203 related articles for article (PubMed ID: 33602645)
21. Comprehensive review of undifferentiated carcinoma of the pancreas: from epidemiology to treatment.
Imaoka H; Ikeda M; Umemoto K; Sunakawa Y; Ueno M; Ueno H; Ozaka M; Kuwahara T; Okano N; Kanai M; Hisano T; Suzuki Y; Asagi A; Shioji K; Todaka A; Tsuji K; Ikezawa K; Miki I; Komatsu Y; Akutsu N; Yamashita T; Okuyama H; Furuse J; Nagano H
Jpn J Clin Oncol; 2023 Aug; 53(9):764-773. PubMed ID: 37325968
[TBL] [Abstract][Full Text] [Related]
22. Quality of life scores as prognostic factors of overall survival in advanced head and neck cancer: analysis of a phase III randomized trial of pemetrexed plus cisplatin versus cisplatin monotherapy.
Urba S; Gatz J; Shen W; Hossain A; Winfree K; Koustenis A; Peterson P; Cohen EE
Oral Oncol; 2012 Aug; 48(8):723-9. PubMed ID: 22414289
[TBL] [Abstract][Full Text] [Related]
23. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.
Arslan D; Bozcuk H; Gunduz S; Tural D; Tattli AM; Uysal M; Goksu SS; Bassorgun Cİ; Koral L; Coskun HS; Ozdogan M; Savas B
Asian Pac J Cancer Prev; 2014; 15(6):2465-72. PubMed ID: 24761848
[TBL] [Abstract][Full Text] [Related]
24. The Prognostic Impact of Histopathological Variants in Patients with Advanced Urothelial Carcinoma.
Hsieh MC; Sung MT; Chiang PH; Huang CH; Tang Y; Su YL
PLoS One; 2015; 10(6):e0129268. PubMed ID: 26114748
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors in clinical stage T4N2 locally advanced non-small cell lung cancer.
Arslan D; Tural D; Koca T; Tastekin D; Kaymak Cerkesli A; Basaran H; Gunduz S; Murat Tatli A; Sezgin Goksu S; Uysal M; Kargi A; Kargi B; Koral L; Ibrahim Bassorgun C; Unal D; Mutlu H; Senol Coskun H; Ozdogan M; Bozcuk H
J BUON; 2015; 20(2):573-9. PubMed ID: 26011352
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy.
Park I; Lee JL; Ryu MH; Kim TW; Sook Lee S; Hyun Park D; Soo Lee S; Wan Seo D; Koo Lee S; Kim MH
Cancer; 2009 Sep; 115(18):4148-55. PubMed ID: 19536892
[TBL] [Abstract][Full Text] [Related]
27. Impact of Tumor-Infiltrating Lymphocytes on Overall Survival in Merkel Cell Carcinoma.
Butala AA; Jain V; Reddy VK; Sebro RA; Song Y; Karakousis G; Mitchell TC; Lukens JN; Shabason JE
Oncologist; 2021 Jan; 26(1):63-69. PubMed ID: 32886418
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the prognostic value of MUST, ECOG-PS, mGPS and CT derived body composition analysis in patients with advanced lung cancer.
Abbass T; Dolan RD; MacLeod N; Horgan PG; Laird BJ; McMillan DC
Clin Nutr ESPEN; 2020 Dec; 40():349-356. PubMed ID: 33183562
[TBL] [Abstract][Full Text] [Related]
29. Important prognostic factors for survival in patients with malignant pleural effusion.
Zamboni MM; da Silva CT; Baretta R; Cunha ET; Cardoso GP
BMC Pulm Med; 2015 Mar; 15():29. PubMed ID: 25887349
[TBL] [Abstract][Full Text] [Related]
30. The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer.
Banna GL; Cortellini A; Cortinovis DL; Tiseo M; Aerts JGJV; Barbieri F; Giusti R; Bria E; Grossi F; Pizzutilo P; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Gelibter A; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Montrone M; Citarella F; Marco R; Cantini L; Nigro O; D'Argento E; Buti S; Minuti G; Landi L; Guaitoli G; Lo Russo G; De Toma A; Donisi C; Friedlaender A; De Giglio A; Metro G; Porzio G; Ficorella C; Addeo A
ESMO Open; 2021 Apr; 6(2):100078. PubMed ID: 33735802
[TBL] [Abstract][Full Text] [Related]
31. Low Geriatric Nutritional Risk Index as a Poor Prognostic Marker for Second-Line Pembrolizumab Treatment in Patients with Metastatic Urothelial Carcinoma: A Retrospective Multicenter Analysis.
Etani T; Naiki T; Sugiyama Y; Nagai T; Iida K; Noda Y; Shimizu N; Tasaki Y; Mimura Y; Okada T; Banno R; Kubota H; Hamamoto S; Ando R; Kawai N; Yasui T
Oncology; 2020; 98(12):876-883. PubMed ID: 32862183
[TBL] [Abstract][Full Text] [Related]
32. Survival Analysis of Advanced HCC Treated with Radioembolization: Comparing Impact of Clinical Performance Status Versus Vascular Invasion/Metastases.
Ali R; Gabr A; Abouchaleh N; Al Asadi A; Mora RA; Kulik L; Abecassis M; Riaz A; Salem R; Lewandowski RJ
Cardiovasc Intervent Radiol; 2018 Feb; 41(2):260-269. PubMed ID: 28879621
[TBL] [Abstract][Full Text] [Related]
33. Comparative analysis of comorbidity and performance indices for prediction of oncological outcomes in patients with upper tract urothelial carcinoma who were treated with radical nephroureterectomy.
Aziz A; Fritsche HM; Gakis G; Kluth LA; Hassan Fa; Engel O; Dahlem R; Otto W; Gierth M; Denzinger S; Schwentner C; Stenzl A; Shariat SF; Fisch M; Burger M; Rink M
Urol Oncol; 2014 Nov; 32(8):1141-50. PubMed ID: 24856977
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer.
Bridgewater J; Lopes A; Wasan H; Malka D; Jensen L; Okusaka T; Knox J; Wagner D; Cunningham D; Shannon J; Goldstein D; Moehler M; Bekaii-Saab T; McNamara MG; Valle JW
Ann Oncol; 2016 Jan; 27(1):134-40. PubMed ID: 26483051
[TBL] [Abstract][Full Text] [Related]
35. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
Cai W; Zhang J; Chen Y; Kong W; Huang Y; Huang J; Zhou L
Chin J Cancer; 2017 May; 36(1):47. PubMed ID: 28521783
[TBL] [Abstract][Full Text] [Related]
36. Significance of serum ferritin as a prognostic factor in advanced hepatobiliary cancer patients treated with Korean medicine: a retrospective cohort study.
Song A; Eo W; Kim S; Shim B; Lee S
BMC Complement Altern Med; 2018 Jun; 18(1):176. PubMed ID: 29879960
[TBL] [Abstract][Full Text] [Related]
37. An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib.
Diaz-Beveridge R; Bruixola G; Lorente D; Caballero J; Rodrigo E; Segura Á; Akhoundova D; Giménez A; Aparicio J
Clin Transl Oncol; 2018 Mar; 20(3):322-329. PubMed ID: 28801777
[TBL] [Abstract][Full Text] [Related]
38. Glasgow prognostic score predicts prognosis for cancer patients in palliative settings: a subanalysis of the Japan-prognostic assessment tools validation (J-ProVal) study.
Miura T; Matsumoto Y; Hama T; Amano K; Tei Y; Kikuchi A; Suga A; Hisanaga T; Ishihara T; Abe M; Kaneishi K; Kawagoe S; Kuriyama T; Maeda T; Mori I; Nakajima N; Nishi T; Sakurai H; Morita T; Kinoshita H
Support Care Cancer; 2015 Nov; 23(11):3149-56. PubMed ID: 25777319
[TBL] [Abstract][Full Text] [Related]
39. Glasgow Prognostic Score is superior to ECOG PS as a prognostic factor in patients with gastric cancer with peritoneal seeding.
Yuan SQ; Nie RC; Chen YM; Qiu HB; Li XP; Chen XJ; Xu LP; Yang LF; Sun XW; Li YF; Zhou ZW; Chen S; Chen YB
Oncol Lett; 2018 Apr; 15(4):4193-4200. PubMed ID: 29541185
[TBL] [Abstract][Full Text] [Related]
40. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
Buttigliero C; Shepherd FA; Barlesi F; Schwartz B; Orlov S; Favaretto AG; Santoro A; Hirsh V; Ramlau R; Blackler AR; Roder J; Spigel D; Novello S; Akerley W; Scagliotti GV
Oncologist; 2019 Jun; 24(6):e251-e259. PubMed ID: 30139835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
